Vivimed Labs has signed definitive agreements to facilitate an investment of $42.5 million by OrbiMed Asia into the Company’s subsidiary, Vivimed Labs Mascarene, the holding entity of the company’s API business, UQUIFA.
The proceeds of this fund raise will be utilized by the company primarily for Debt reduction and optimization of capital structure at the parent entity level and investment in the API business for capacity augmentation and organic growth.
Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.
